Broadband Collaborative Pulse Ablation Instrument Treating Malignant Pulmonary Nodules

Inclusion Criteria: 1. Age: between 18 and 70 years old with no gender limitation; 2. Malignant pulmonary nodules diagnosed by cytology and/or histopathology, or the number of tumors ≤3. The pulmonary nodules were oligometastatic and the primary lesions were stable, with no uncontrolled metastasis to other sites; 3. Surgery is not available or the patient refuses surgical treatment; 4. Nodules' Maximum diameter≤2cm; 5. ECOG score≤2; 6. Patients understood the trial procedure and voluntarily signed informed consent. Exclusion Criteria: 1. An electronic device is implanted near the target area or an implanted pacemaker or defibrillator is present in the body; 2. Coagulation dysfunction with severe bleeding tendency and short-term correction (prothrombin time \>18s, prothrombin activity \<40%, platelet \<80×109 /L); 3. Patient who can not stop taking Antiplatelet and anticoagulant drugs 5 days before surgery; 4. Severe pulmonary fibrosis and pulmonary hypertension; 5. Patients with poor control of pleural effusion; 6. Patients with serious insufficiency of Liver, kidney, heart, lung, and brain function; 7. Patients with Severe anemia, dehydration, and severe disturbance of nutrient metabolism, which cannot be corrected or improved in the short term; 8. Patients with severe systemic infection, high fever (\>38.5℃); 9. Pregnant and lactating women and those planning to become pregnant within one year; 10. Participants in clinical trials of any drugs and/or medical devices within 3 months before enrollment; 11. Any other factors that the investigator considers inappropriate for inclusion or that may affect the subject's participation in the study.